Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects.

Authors not listed

SIPO Biotechnology Co. Ltd. · 2027

Dysbiosis Human Randomized controlled trial

Abstract

This is a first-in-human, randomized, double-blind, placebo-controlled clinical study to evaluate the Safety and Tolerability of SPOT-mRNA01 injection in healthy adult volunteers.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-05-29 MST

Cite this

APA

Anonymous. (2027). A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects. <em>SIPO Biotechnology Co. Ltd.</em>. https://clinicaltrials.gov/study/NCT06567119

Vancouver

Anonymous. A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects. SIPO Biotechnology Co. Ltd.. 2027.

BibTeX

@misc{anon2027ARando, title = {A Randomized, Double-blind, Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects.}, author = {Anonymous}, journal = {SIPO Biotechnology Co. Ltd.}, year = {2027}, }